Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

About this Study

The purpose of this study is to test the good and bad effects of the study drug Rucaparib. Another purpose of this study is to learn if a biomarker test for LOH or BRCA1 or BRCA2 genes is helpful in assigning treatment.

Sponsor Protocol ID:S1900A
IRB Number:2019-0049
Closed for Enrollment
Interventional
Phase 2
May 28, 2019
Eligibility Criteria
Both Male and Female
Yes
No
No

Inclusion CriteriaThis study was designed to include women and minorities but was not designed to measure differences of intervention effects.

Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Preventive Medicine
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:John Ruckdeschel
How to participate in our Clinical Trials